U.S. markets open in 1 hour 54 minutes

CHF Solutions, Inc. (CHFS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.79-0.27 (-3.82%)
At close: 4:00PM EDT

6.30 -0.49 (-7.22%)
Before hours: 4:15AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close7.06
Open7.09
Bid6.33 x 1200
Ask0.00 x 800
Day's Range6.66 - 7.32
52 Week Range0.28 - 7.36
Volume624,702
Avg. Volume10,161,120
Market Cap18.577M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-37.45
Earnings DateAug 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CHF Solutions (CHFS) Enters Oversold Territory
    Zacks

    CHF Solutions (CHFS) Enters Oversold Territory

    CHF Solutions (CHFS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire

    CHF Solutions Announces Data Demonstrating Benefit of Aquadex Therapy for Treatment of Heart Failure and COVID-19

    EDEN PRAIRIE, Minn., Oct. 07, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced data from a retrospective study and a case study supporting the benefit of Aquadex™ therapy in the treatment of heart failure. These data were presented at the 24th Annual Scientific Meeting of Heart Failure Society of America. The real-world retrospective study of 335 patients treated with the Aquadex FlexFlow® System, “10 years of real world data with UF for ADHF patients,”1 compared previous RCT trials with ultrafiltration (UF) and demonstrated that UF compares favorably in reducing heart failure (HF) rehospitalizations, renal function response, and weight/volume loss. Specific results included: * Substantial mean fluid removal (14.58 liters) and weight loss (15.63 lbs), which was sustained at 1-2 weeks post follow-up. * Improvement in reduced HF rehospitalization rates at 30, 90 days, and 1 year of 12.4%, 14.9%, 27.3% respectively. * Mean serum creatinine (sCr) increase of +0.07-0.11 mg/dl recorded at time of stopping therapy, discharge, and follow up. * On average, patients had 1.74 fewer hospitalizations for HF in the year following UF when compared to the year preceding UF. * Major bleeding, defined as requiring discontinuation of anticoagulation, was 3.6 % In comparison to previous randomized control trials focused on UF (AVOID2, CARRESS3, DOSE4, and UNLOAD5), patients in this study were older with worse renal function and greater HF hospitalizations in the year preceding UF therapy. The ability to adjust the rate of fluid removal with the Aquadex system is believed to be a major contributor to favorable outcomes. The study was conducted by Abington Hospital – Jefferson Health in Abington, Pennsylvania and funded by CHF Solutions.The case study, “Outpatient Ultrafiltration to Prevent Hospital Readmissions During COVID-19 Pandemic in Diuretic Intolerant Patient: Case Study,”6 involved the successful outpatient treatment of a 70-year-old female with heart failure with preserved ejection fraction and pre- and post-capillary pulmonary hypertension. This patient did not respond to outpatient therapies and diuretics and experienced multiple hospitalizations due to recurrent congestion. Given the patient’s co-morbidities and high-risk status, the patient received UF treatment with the Aquadex SmartFlow™ system in an outpatient setting to avoid exposure to COVID-19. Over the course of 4 days, a total of 4950 ml of isotonic fluid was removed. The patient showed immediate improvement in clinical symptoms and was effectively stabilized in the outpatient setting at Advocate Good Samaritan Hospital in Downers Grove, Illinois.“We are pleased with the results of these two studies confirming the benefits of Aquadex therapy in the treatment of heart failure patients, as demonstrated in previous studies and clinical observations, and the effectiveness of use in the outpatient setting to limit exposure to COVID-19,” said John Erb, Chairman and CEO of CHF Solutions. “We thank the teams at Abington Hospital – Jefferson Health and Advocate Good Samaritan Hospital for furthering data on the benefits of ultrafiltration.” 1. https://www.chf-solutions.com/aquadex-smartflow-system/clinical-evidence/ 2. AVOID-HF Trial: https://pubmed.ncbi.nlm.nih.gov/26519995/ 3. CARRESS-HF Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa1210357 4. DOSE Trial: https://pubmed.ncbi.nlm.nih.gov/21366472/ 5. UNLOAD Trial: https://pubmed.ncbi.nlm.nih.gov/17291932/ 6. https://www.chf-solutions.com/aquadex-smartflow-system/clinical-evidence/About CHF Solutions CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the use of Aquadex therapy in the treatment of heart failure and COVID-19. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CONTACTSINVESTORS:Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.comMEDIA:Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com

  • GlobeNewswire

    CHF Solutions Initiatives at HFSA 24th Annual Scientific Meeting Highlight Aquadex Therapy Performance in Heart Failure

    EDEN PRAIRIE, Minn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced its initiatives for the 24th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) from September 30 to October 6, 2020. The conference is being held this year on a virtual platform at https://hfsa.org/annualscientificmeeting/program. Key highlights on Aquadex™ Therapy at VirtualHFSA2020 include: * Clinical Study Data from “Ten Year Experience of Ultrafiltration for Management of Acute Decompensated Heart Failure (ADHF)” presented during the Live Poster Chats on Saturday, October 3 and Sunday, October 4 from 1:15 to 2:45pm ET. * Case Study on “Outpatient Ultrafiltration to prevent Hospital Readmission During COVID-19 Pandemic in Diuretic Intolerant Patient: Case Study” presented during the Live Poster Chats on Saturday, October 3 and Sunday, October 4 from 1:15 to 2:45pm ET. * Virtual booth at https://virtual.hfsa.org/node/301597/exhibithall/0/422944lct=exhibithall-422944 with an opportunity to ask questions of CHF Solutions’ clinical specialists and access educational materials regarding the treatment of heart failure patients, including the recent webinar “Precision Medicine for the Treatment of Fluid Overload in Patients with Acute Heart Failure” presented by Dr. John Jefferies, the Jay M. Sullivan Distinguished Chair in Cardiovascular Medicine and Chief of Cardiology at the University of Tennessee Health Science Center. “This year’s virtual platform provides medical professionals with efficient access to valuable information and clinical data. We are excited to share how the Aquadex system has proven to be advantageous in the delivery of effective care for heart failure patients and patients with COVID-19,” said John Erb, Chairman and CEO of CHF Solutions. “We look forward to the presentation of additional data involving the use of ultrafiltration in the treatment of heart failure during the conference.”About CHF Solutions CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow™ system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the company’s initiatives in connection with the 24th Annual Scientific Meeting of the Heart Failure Society of America. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. CONTACT: CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com MEDIA: Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com